Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry
نویسندگان
چکیده
Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure clinical routine, data on TKI stopping outside are limited. In this retrospective study utilising the Swedish registry, we examined discontinuation a population-based setting. Out of 584 diagnosed chronic-phase (CML-CP) 2007–2012, 548 had evaluable information discontinuation. With median follow-up nine years from diagnosis, 128 (23%) therapy (≥1 month) due to achieving DMR (deep molecular response) and 107 (20%) other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those DMR, 49% re-initiated (median time restart 4·8 months). all, 38 stopped within 90 study. After 24 months 41·1% discontinuing treatment. duration pre-stop was longer proportion treated second-generation slightly higher studies, conceivably affecting outcome. summary practice is common feasible may just as successful when performed trial.
منابع مشابه
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Even in the tyrosine kinase inhibitors era, the prognosis of patients with chronic myeloid leukaemia in myeloid blast crisis remains dismal with few patients surviving longer than 6 months. Here we report the cases of 5 patients treated with the combination of 5-azacytidine and tyrosine kinase inhibitors for myeloid blast crisis CML. All patients achieved a complete haematological response incl...
متن کاملTyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
For most patients with chronic myeloid leukemia, tyrosine kinase inhibitors (TKIs) have turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI granted regulatory approval, has been surpassed in terms of molecular responses by the second-generation TKIs nilotinib, dasatinib, and bosutinib. Recently, ponatinib was approved as the only TKI with activity agains...
متن کاملTyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious consequence of some of the newer TKIs. In this review, we describe the clinical spectrum of TKI-...
متن کاملTailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
BACKGROUND Research into chronic myeloid leukemia (CML) is increasingly focused on the problem of imatinib failure. Dasatinib and nilotinib are both active in chronic- and accelerated-phase CML, including patients with imatinib-resistant or intolerant disease. METHODS This paper reviews advances in tailoring tyrosine kinase inhibition therapy according to patient risk profiles as well as hema...
متن کاملUnfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
Dna2 was first characterized in yeast as an essential gene encoding a protein with both helicase and endonuclease activities involved in maturation of Okazaki fragments during DNA replication. Dna2 also plays a role in double-strand break (DSB) repair by homolo-gous recombination. The respective contributions of its replication and/or repair functions toward cell viability and resistance to gen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2021
ISSN: ['0007-1048', '1365-2141']
DOI: https://doi.org/10.1111/bjh.17392